Biotechnology Assets (BST) | Stock Overview & Key Data
Biotechnology Assets S.A. | Small-cap | Healthcare
Biotechnology Assets S.A. | Small-cap | Healthcare
Biotechnology Assets Performance Comparison
Stock Range
Today's Range
Low: €0.35
High: €0.37
on August 8, 2025
52 Week Range
Low: €0.24
High: €0.49
on November 12, 2024
on July 1, 2025
All-Time High: €13.98 on June 23, 2014
Explore how other Spanish stocks compare to their 52-week ranges: View ES Market 52-Week Insights
Key Statistics
Market Cap
€24.1M
EPS
-0.04
P/E Ratio (TTM)
10.77
Forward P/E
N/A
P/B Ratio
3.56
PEG Ratio
-0.04
Div. Yield
N/A
ROE
-44.40%
Beta
1.648
Debt to Equity
31.56
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-38.88%
Profit Margin
-98.39%
Returns and Earnings
Return on Assets (TTM)
-9.11%
Return on Equity (TTM)
-44.40%
EBITDA
€-1.3M
Net Income (TTM)
€-2.9M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€0.05
Quarterly Revenue Growth (YoY)
-18.00%
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Assets BST | 24.09M Small-cap | 0.00% | -12.20% | 24.14% | 0.00% | 28.57% | 16.13% | 89.47% | -53.85% |
| Pharma Mar S.A PHM | 1.41B Large-cap | -1.68% | -5.57% | 7.28% | -13.02% | -1.50% | 116.43% | 25.69% | -6.61% |
| Atrys Health S.A ATRY | 214.06M Mid-cap | -4.11% | 8.95% | -5.08% | -21.79% | -20.00% | -7.89% | -54.55% | -62.57% |
| Vytrus Biotech S.A VYT | 41.38M Small-cap | -9.09% | 22.22% | 70.81% | 133.05% | 154.63% | 71.34% | 77.42% | 95.04% |
| Oryzon Genomics S.A ORY | 203.86M Mid-cap | -2.65% | -4.46% | -3.38% | 72.48% | 71.33% | 48.57% | 1.17% | -4.41% |
| Grifols, S.A GRF | 7.93B Large-cap | -2.06% | 22.50% | 57.28% | 54.08% | 35.84% | 46.52% | -6.61% | -47.55% |
Ownership & Short Interest
Insider Ownership
40.72%
Institutional Ownership
0.10%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
155K
Average 90-Day Volume
472K
Biotechnology Assets Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Biotechnology Assets would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is BST's 52-week high and low?
- In the last 52 weeks, Biotechnology Assets reached a high of €0.49 (on July 1, 2025) and a low of €0.24 (on November 12, 2024).
- What is the market cap and P/E ratio for BST?
- Curious about Biotechnology Assets's size and valuation? Its market capitalization stands at 24.09M. When it comes to valuation, the P/E ratio (trailing twelve months) is 10.77, and the forward P/E (looking ahead) is N/A.
- Does BST pay dividends? If so, what's the yield?
- As for dividends, Biotechnology Assets isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Biotechnology Assets's main competitors or similar companies to consider before investing?
When looking at Biotechnology Assets, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Pharma Mar S.A
PHM1.41B Healthcare Biotechnology 116.43% 25.69% Atrys Health S.A
ATRY214.06M Healthcare Biotechnology -7.89% -54.55% Vytrus Biotech S.A
VYT41.38M Healthcare Biotechnology 71.34% 77.42% Oryzon Genomics S.A
ORY203.86M Healthcare Biotechnology 48.57% 1.17% Grifols, S.A
GRF7.93B Healthcare Drug Manufacturers - General 46.52% -6.61% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Biotechnology Assets S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Biotechnology Assets's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -44.40%, the Debt to Equity ratio from the most recent quarter is 31.56, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for BST?
- Looking at Biotechnology Assets's growth, its revenue over the trailing twelve months (TTM) was €3M. Compared to the same quarter last year (YoY), quarterly revenue grew by -18.00%, and quarterly earnings saw a YoY growth of N/A.
- How much of BST stock is held by insiders and institutions?
- Wondering who owns Biotechnology Assets stock? Company insiders (like executives and directors) hold about 40.72% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.10%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.